Back to top
more

Johnson & Johnson (JNJ)

(Real Time Quote from BATS)

$152.93 USD

152.93
1,539,396

-2.11 (-1.36%)

Updated Nov 12, 2024 11:22 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 249)

Industry: Large Cap Pharmaceuticals

Zacks News

Will AbbVie's Immunology Drugs Continue to Drive Q3 Earnings?

AbbVie's (ABBV) third-quarter performance is expected to reflect the impact of strong demand for immunology and aesthetics products.

The Zacks Analyst Blog Highlights J&J, Roche, Eli Lilly and AbbVie

J&J, Roche, Eli Lilly and AbbVie are part of The Zacks top Analyst Blog.

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?

AbbVie (ABBV) third-quarter performance will likely reflect the impact of strong demand for immunology and aesthetics franchises. Investors will also enquire about ABBV's plans to counter Humira LOE.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ Q3 Earnings Beat, RHHBY Sales Weak, LLY, ABBV Ink M&A Deals

J&J (JNJ) beats earnings and sales estimates for the third quarter. Eli Lilly (LLY) and AbbVie (ABBV) announce small acquisitions.

Legend's (LEGN) Q3 Carvykti Preliminary Sales Top Expectations

Legend Biotech (LEGN) reports $55 million as preliminary sales figures for its multiple myeloma therapy in third-quarter 2022. Shares rise 14.2% post the announcement.

Sweta Killa headshot

JNJ Beats on Q3 Earnings: ETFs in Focus

Johnson & Johnson (JNJ) continued with its long streak of earnings beat. It outpaced revenue estimates and raised its full-year revenue guidance.

Stock Market News for Oct 19, 2022

U.S. stocks ended higher on Tuesday for the second straight day as another batch of solid earnings reports gave investors' confidence a boost.

J&J (JNJ) Beats on Q3 Earnings, Cuts 2022 Sales View on Fx Woes

J&J (JNJ) beats estimates for third-quarter earnings as well as sales. It lowers the full-year sales guidance. Stock up

Pre-Markets in the Green on Strong Earnings Numbers

Pre-Markets in the Green on Strong Earnings Numbers

Mark Vickery headshot

Pre-Markets Rally on Q3 Beats from J&J, Goldman

With the Dow +640 points at this hour, the Nasdaq +280 and the S&P 500 +85 points, it's safe to say we're in the midst of a rally.

Johnson & Johnson (JNJ) Tops Q3 Earnings and Revenue Estimates

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 2.41% and 2.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Q3 Earnings Season to Gather Pace This Week

Q3 Earnings Season to Gather Pace This Week

Mark Vickery headshot

Pre-Markets Up to Start a New Week

The Dow is +350 points ahead of the open, the S&P is +50 and the Nasdaq is +160 points.

Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Is ALPS O'Shares U.S. Quality Dividend ETF (OUSA) a Strong ETF Right Now?

Smart Beta ETF report for OUSA

Sheraz Mian headshot

Can Bank Stocks Maintain the Recent Momentum?

The market liked what it saw in the quarterly releases from JPMorgan (JPM), Citigroup (C) and even Wells Fargo (WFC) on an otherwise down day for the indexes.

Derek Lewis headshot

Johnson & Johnson Q3 Preview: Can the Earnings Streak Continue?

JNJ has a stellar earnings track record, exceeding the Zacks Consensus EPS Estimate in each quarter dating all the way back to 2012.

Why Johnson & Johnson (JNJ) is Poised to Beat Earnings Estimates Again

Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector

J&J's (JNJ) Pharma segment is expected to have performed above the market. In the MedTech segment, sales in the second half are expected to have been better than the first.

Sweta Killa headshot

Dow ETFs in Focus Ahead of Q3 Earnings

After the worst first nine months of 2022, the Dow Jones Industrial Average showed some stability at the start of the fourth quarter.

Earnings Preview: Johnson & Johnson (JNJ) Q3 Earnings Expected to Decline

Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know

In the latest trading session, Johnson & Johnson (JNJ) closed at $160.41, marking a +0.13% move from the previous day.